BTP Viewed As Glomerular Filtration Rate Marker
|
By LabMedica International staff writers Posted on 24 Apr 2018 |

Image: The N Latex Cystatin C Assay for the detection of decline in renal function (Photo courtesy of Siemens Healthcare).
Beta Trace Protein (BTP) is a promising marker of glomerular filtration rate (GFR) as it was reported to be increased in the serum of patients with renal disease. Some evidence suggests that it is more sensitive than creatinine (Cr) at detecting early changes in GFR.
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Latest Immunology News
- Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
- Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
- Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
- Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
- Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
- Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
- Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
- Compact Immunoanalyzer Gains CE Mark for Testing Across Local Care Settings
- COVID-19 and Flu Combo Test Launches With FDA Clearance
- Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
- Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
- Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
- Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
- Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
- FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
- Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Channels
Clinical Chemistry
view channel
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channelGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read more
Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







